



**COLORADO**

Department of Health Care  
Policy & Financing

**Drug Utilization Review Board**  
**Health First Colorado (Colorado's Medicaid program)**

**MEETING AGENDA**

**February 10, 2026**

Open Session 1:00 pm to 5:00 pm

Zoom Link will be posted prior to the meeting at  
<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

**DUR Board Members**

Liza Claus, PharmD (Chair)  
Brian Jackson, MD, MA (Vice Chair)  
Marshal Ash, DO  
Todd Brubaker, DO  
Stephanie Cho, PharmD  
Shilpa Klocke, PharmD  
Kenneth MacIntyre, DO  
Ingrid Pan, PharmD

**DUR Team**

Jeffrey Taylor, PharmD (HCPF)  
Julia Rawlings, PharmD (CO-DUR)  
Robert L Page II, PharmD, MSPH (CO-DUR)  
Gina Moore, PharmD, MBA (CO-DUR)  
Heather Anderson, PhD (CO-DUR)  
Garth Wright, MPH (CO-DUR)  
Idana Espinoza, PharmD, MPH (HCPF)  
Mouna Dardouri, PharmD, MPH, PhD student (CO-DUR)

- 1. Call to Order**
- 2. Roll Call and Introductions**
- 3. Virtual Meeting Information and General Announcements**
- 4. Election of DUR Board Chair and Vice Chair**
- 5. Colorado Department of Health Care Policy and Financing Updates**
- 6. Final Approval of Minutes from the November 4, 2025 Meeting**
- 7. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest**

Presentations:

  - Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist Jeffrey Taylor at [jeffrey.taylor@state.co.us](mailto:jeffrey.taylor@state.co.us)
  - Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours prior to the start of the meeting
- 8. Clinical Updates and General Orders**
  - a. FDA Drug Safety Communications Report
  - b. FDA New Approvals Report
  - c. Quarterly Clinical Module Summary
  - d. Retrospective DUR Reports
  - e. Quarterly Drug Utilization Reports

## 9. New Business (open for public testimony and DUR Board review)

### A. Proposed Coverage Criteria for Preferred Drug List (PDL) Drug Classes

(Current PDL available for reference at <https://hcpf.colorado.gov/pharmacy-resources#PDL>)

#### Full review drug classes

- Anticonvulsants, Oral
- Atypical Antipsychotics
  - Oral
  - Topical
- Calcitonin Gene-Related Peptide Inhibitors (CGRPis)
- Neurocognitive Disorder Agents
- Newer Generation Antidepressants
- Stimulants and Related Agents
- Skeletal Muscle Relaxants
- Triptans, Ditans and Other Migraine Treatments
  - Oral
  - Non-Oral
- Ophthalmics, Glaucoma
- Ophthalmics, Immunomodulators

#### Mass Review Drug Classes\*

- Anti-Parkinson's Agents
- Anxiolytics, non-benzodiazepines
- Benzodiazepines, non-sedative hypnotic
- Fentanyl Preparations (buccal, transmucosal, sublingual)
- Lithium Agents
- Monoamine Oxidase Inhibitors (MAOIs)
- Multiple Sclerosis Agents
- Non-Opioid Analgesia Agents
  - Oral
  - Topical
- Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
  - Oral
  - Non-Oral
- Ophthalmics, Allergy
- Ophthalmics, Anti-Inflammatory Agents (NSAID, corticosteroid)
- Opioids
  - Short Acting
  - Long Acting
- Sedative Hypnotics
  - Benzodiazepine
  - Non-Benzodiazepine)
- Tricyclic Antidepressants (TCAs)

*\*Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review, based on board vote.*

## B. Proposed Coverage Criteria for Non-PDL Products

(Current coverage criteria for non-PDL products can be referenced on Appendix P at <https://hcpf.colorado.gov/pharmacyresources#PDL> for the pharmacy benefit and on Appendix Y at <https://hcpf.colorado.gov/physician-administered-drugs> for the medical benefit. Products listed below that are undergoing initial review of newly proposed criteria will not be listed on the posted documents until such time that proposed criteria undergoes review and finalization)

- **VYVGART** (efgartigimod alfa) and **VYVGART HYTRULO** (efgartigimod alfa/hyaluronidase) - Pharmacy and Medical Benefit
- **JASCAYD** (nerandomilast)
- **LYNKUET** (elinzanetant)
- **DAXXIFY** (botulinum toxin type a) - Medical Benefit Only
- **ASCENIV** (human immunoglobulin) - Medical Benefit Only
- **RHAPSIDO** (remibrutinib)
- **FORZINITY** (elamipretide)
- **PALSONIFY** (paltusotine)

## 10. Adjournment

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator or send an email to [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.